Why Is RAPPORT THERAPEUTICS Equity (RAPP) Stock Up Today?

By the Top Tier Newswire AI Desk · October 20, 2026 at 10:17 AM ET · reviewed against 12 wire stories

RAPPORT THERAPEUTICS Equity (RAPP) is up +6.56% in the latest session. Our newswire has captured 12 stories on RAPP across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 71/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Rapport Therapeutics shares climbed 6.56% to close at $30.48 on Tuesday. The primary driver was the announcement of positive topline Phase 2 results for RAP-219, the company’s lead asset for acute bipolar mania. The data showed statistically significant improvements in mania symptoms, meeting both primary and secondary endpoints.

What Happened

Rapport Therapeutics reported that RAP-219 achieved a statistically significant 3.1-point placebo-adjusted improvement in the YMRS score at Week 3 in its Phase 2 trial. The company stated that the results met both primary and secondary endpoints. Management plans to initiate Phase 3 studies in 2027. Analysts responded with mixed but generally positive commentary. Wells noted that the efficacy data looks good but flagged some questions regarding safety. BTIG maintained a Buy rating on the stock and raised its price target to $89. The stock had previously traded in a narrow range, moving down 4.2% over the eight sessions prior to this announcement.

What The Data Shows

The stock opened at $35.68, representing a 24.8% gap up from the prior close of $28.60. Trading volume reached 3.0 million shares, which is 7.7 times the three-month daily average. The session high was $40.25 at 7:25 AM ET, while the session low was $26.73 at 9:35 AM ET. The company has a market capitalization of $1.3 billion and remains unprofitable with a trailing twelve-month EPS of -3.05. The stock has a beta of 1.22 and a 52-week range of $23.75 to $52.93. On the date of the announcement, the stock printed two fresh 52-week highs and three fresh 52-week lows. Insider activity has been predominantly selling, with nine sales totaling $7.0 million in the last 90 days and no buys. Recent Form 4 filings include sales by CEO Ceesay Abraham and COO Cheryl Gault.

What To Watch

Investors will monitor the company’s plans for Phase 3 trials scheduled for 2027. The stock currently has 12 stories from 9 sources in the last 36 hours, indicating high coverage breadth.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

RAPP by the numbers

Last: $30.48Session: +6.56%7 sessions: -4.19%Coverage: 12 stories / 9 sourcesAI sentiment: 71/100 (bullish)Mkt cap: $1.3B52w: $23.75 to $52.93

RAPP · today's session (5-min) · +6.24% vs prior close · updated 2:53 PM ET

AI sentiment, last 36h · averaged over 12 stories · 71/100 bullish

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline

5h agoBarron'sBULLISH 74General

Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging

6h agoInvestors.comBULLISH 64Product/PR

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher

Rapport Therapeutics stock shot higher Tuesday on promising, but mixed, test results for its bipolar treatment.

7h agoThe FlyBULLISH 58Product/PR

Wells says Rapport’s RAP-219 efficacy looks good, flags some questions on safety

8h agoMarketChameleonBULLISH 74Product/PR

Rapport’s RAP-219 posts statistically significant Week 3 mania improvements in Phase 2 bipolar trial October 20, 2026

Rapport Therapeutics reported positive topline Phase 2 results for RAP-219 in acute bipolar mania, meeting both primary and secondary endpoints with a statistically significant 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045) and a 0.4-point CGI-BP mania severity improvement (p=0.024). Safety during the three-week treatment period appeared comparable to placebo, with no serious adverse events reported and TEAE rates of 51.6% vs 52.8%.

8h agoInvestorsHubBULLISH 82Product/PR

Rapport Therapeutics Shares Rise Over 50% Premarket as RAP-219 Meets Phase 2 Bipolar Mania Trial Endpoints

Rapport Therapeutics (NASDAQ:RAPP) shares rise over 50% as RAP-219 meets Phase 2 bipolar mania trial endpoints, with Phase 3 studies planned for 2027.

8h agoInvesting.com MarketsBULLISH 74General

Why is Rapport Therapeutics stock surging 31% today?

8h agoBusiness InsiderBULLISH 74Product/PR

Rapport climbs as lead asset succeeds in mid-stage trial for bipolar mania

Rapport Therapeutics (RAPP) stock jumps as lead asset RAP-219, succeeds in a mid-stage trial for adults with acute bipolar mania. Read more here.

8h agoInvesting.com MarketsBULLISH 84Product/PR

Rapport Therapeutics soars over 50% as bipolar mania drug meets trial goals

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on RAPP: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier RAPP move explainers: 2026-10-20 · 2026-09-24 · 2026-09-23